Common name
(4-chlorophenyl)urea
IUPAC name
(4-chlorophenyl)urea
SMILES
O=C(Nc1ccc(cc1)Cl)N
Common name
(4-chlorophenyl)urea
IUPAC name
(4-chlorophenyl)urea
SMILES
O=C(Nc1ccc(cc1)Cl)N
INCHI
InChI=1S/C7H7ClN2O/c8-5-1-3-6(4-2-5)10-7(9)11/h1-4H,(H3,9,10,11)
FORMULA
C7H7ClN2O
Common name
(4-chlorophenyl)urea
IUPAC name
(4-chlorophenyl)urea
Molecular weight
170.596
clogP
0.839
clogS
-2.044
Frequency
0.0010
HBond Acceptor
1
HBond Donor
3
Total PolarSurface Area
55.12
Number of Rings
1
Rotatable Bond
1
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00278 | Sorafenib |
|
Antineoplastic Agents; Immunosuppressive Agents; Protein Kinase Inhibitors; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; | Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. |
| FDBD01561 | Regorafenib |
|
Antineoplastic Agents; Protein Kinase Inhibitors; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; | Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. |
| FDBD02319 | flucofuron |
|
Insecticide | Insecticide |
3 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 3heg_ligand_1_0.mol2 | 3heg | 1 | -7.13 | C(=O)(Nc1ccc(cc1)Cl)N | 11 |
| 3gcs_ligand_1_0.mol2 | 3gcs | 1 | -7.10 | c1c(ccc(c1)Cl)NC(=O)N | 11 |
| 2q1j_ligand_1_2.mol2 | 2q1j | 1 | -6.98 | c1(ccc(cc1)Cl)NC(=O)N | 11 |
| 1uwh_ligand_1_0.mol2 | 1uwh | 1 | -6.90 | C(=O)(Nc1ccc(cc1)Cl)N | 11 |
| 1bju_ligand_1_1.mol2 | 1bju | 1 | -6.11 | c1(ccc(cc1)Cl)NC(=O)N | 11 |
| 2q1j_ligand_2_18.mol2 | 2q1j | 0.925 | -7.11 | c1(ccc(cc1)Cl)NC(=O)NC | 12 |
| 3heg_ligand_2_0.mol2 | 3heg | 0.902439 | -8.77 | C(=O)(Nc1ccc(cc1)Cl)Nc1ccccc1 | 17 |
| 3gcs_ligand_2_0.mol2 | 3gcs | 0.902439 | -8.68 | c1c(ccc(c1)Cl)NC(=O)Nc1ccccc1 | 17 |
112 ,
12
